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Conclusions 12 months of GH treatment lead to a 
decrease in insulin sensitivity and impairment in insulin 
secretion relative to insulin sensitivity even without evi-
dent changes in glucose tolerance. DIo has proven to be the 
most useful indicator of deterioration of glucose metabo-
lism even in cases in which the overt glucose abnormalities 
have not yet appeared.
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Introduction
Growth hormone (GH), in addition to promote linear 
growth during childhood, plays a key metabolic role [1]. Is 
well known that untreated GH deficiency (GHD) in chil-
dren, as well as in adults, is associated with cardiovascular 
risk factors such as abnormalities in body composition with 
increased visceral fat, increased peripheral inflammatory 
markers and dyslipidemia and GH treatment seems to exert 
beneficial effects on most of these alterations [2–4]. On the 
other hand, the anti-insulin effect of GH can induce impor-
tant changes in glucose metabolism. The acute adminis-
tration of GH has an early insulin-like and a later insulin-
antagonist effect on carbohydrate metabolism [5–7], while 
continuous GH infusion induces acute insulin resistance 
characterized by impaired suppression of hepatic glucose 
production and decreased insulin-dependent glucose dis-
posal [8–10]. GH treatment has therefore been suggested 
to impair glucose metabolism [9, 11, 12] and monitoring of 
glucose levels during GH treatment has been recommended 
in GHD subjects with diabetes mellitus risk factors because 
of the evidence of higher incidence of diabetes than the 
general population [13, 14].
Abstract 
Purpose To evaluate the performance of various indexes 
of insulin sensitivity and secretion and to identify the most 
useful indicator of deterioration of glucose metabolism in 
a cohort of children with growth hormone (GH) deficiency 
(GHD) during GH treatment.
Methods In 73 GHD children (55 M, 18 F; mean age 
10.5 years) at baseline and after 12 months of treatment, 
we evaluated a number of surrogate indexes of insulin 
secretion and sensitivity. In a subgroup of 11 children we 
also performed an euglycemic hyperinsulinemic clamp.
Results After 12 months, a significant increase in fasting 
glucose (p < 0.001) and HbA1c levels (p < 0.001) was doc-
umented, despite all children remained with a normal glu-
cose tolerance. With regard the insulin secretion, Homa-β 
did not show any significant change (p = 0.073), while 
oral disposition index (DIo) showed a significant decrease 
(p = 0.031). With regard the insulin sensitivity, Homa-
IR significantly increased (p < 0.001) with a concomitant 
decrease in QUICKI (p < 0.001). ISI Matsuda showed a 
decrease, although not statistically significant (p = 0.069). 
In the subgroup of 11 children, the M value derived from 
clamp showed a significant decrease (p = 0.011) and a sig-
nificant positive correlation was found between M value 
and ISI Matsuda both at baseline (ρ 0.950; p = 0.001) and 
after 12 months (ρ 0.980; p = 0.001) but not with Homa-IR 
and QUICKI.
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Exhaustive studies about the mechanism by which the 
glucose metabolism may worsen during GH replacement 
treatment are still scarce. Various and conflicting surrogate 
indices have been used to assess the best way to evaluate 
it, but with discordant results. Thus, the objective of this 
study was to assess any difference in insulin sensitivity 
and secretion indexes between untreated GHD and healthy 
children and to evaluate the performance of these indexes, 
identifying the most useful indicator of deterioration of 
glucose metabolism, in the GHD group during a follow-up 
of 12 months of GH treatment.
Materials and methods
We prospectively studied 73 children (55 M, 18 F; mean 
age 10.5 ± 2.8 years; range 4.3–15) with isolated idi-
opathic GHD consecutively admitted to the Section 
of Endocrinology of the University of Palermo during 
the years 2010–2012 and treated with GH for at least 
12 months. Fifty healthy subjects, matched for sex (37 M, 
13 F), age (mean age 10.3 ± 2.8 years; range 5.1–13.2) 
and pubertal status, were recruited among children 
referred for the assessment of short stature as a control 
group of GHD children at baseline. We excluded chil-
dren affected by multiple pituitary hormone deficiency or 
receiving any other kind of hormonal replacement treat-
ment or drug and with a follow-up of less than 12 months. 
All children, even the older ones, were in the first or sec-
ond stage of sexual development according to the criteria 
of Marshall and Tanner [15] to avoid any interference of 
puberty on insulin sensitivity degree. In particular, among 
GHD children, the pubertal status was stage I in 63 (54 
M, 9 F) and stage II in 10 (8 M, 2 F) subjects at baseline, 
and stage I in 54 (48 M, 6 F) and stage II in 19 (14 M, 5 
F) subjects after 12 months, while in the control group 44 
children (39 M, 5 F) were in the stage I and 6 (4 M, 2 F) 
in the stage II.
The diagnosis of GHD was established by the clinical, 
auxological and biochemical criteria of the GH Research 
Society [16]. GHD was demonstrated by failure of GH 
to respond to the two stimuli (arginine and glucagon test) 
with GH peaks below 10 µg/l. The patients received GH 
once daily at bedtime with a pen injection system. Dur-
ing the follow-up, IGF levels and the growth velocity 
have allowed us to utilize in all children the GH dose in 
line with our internal fixed protocol, with an initial daily 
dose of 0.025 mg/kg and a gradual increase of 0.004 mg/
kg/day every 3–6 months. From months 1 to 3 all children 
were maintained at a mean dose of 0.025 mg/kg/day, from 
months 3 to 9 at 0.029 mg/kg/day and from months 9 to 12 
at 0.033 mg/kg/day. IGF-I levels were maintained during 
the entire follow-up within the normal range for age.
Study protocol
In all patients, after the diagnosis of GHD was made, at 
baseline and after 12 months of GH treatment, according 
to our fixed internal protocol, we measured body height 
(standard deviation SD), body mass index (BMI and BMI 
z-score) and waist circumference (WC).
On day 1, blood sample was drawn after an overnight 
fast for the measurement of fasting glucose, fasting insu-
lin, Hemoglobin A1c (HbA1c) and IGF-I. This sample also 
served as the baseline sample for an oral glucose tolerance 
test (OGTT). Blood samples were collected every 30 min 
for 2 h for glucose and insulin measurements. The area 
under the curve (AUC) of glucose (AUCGLU) and insulin 
(AUCINS) during OGTT was calculated using the trapezoi-
dal rule.
Estimates of basal insulin secretion included fasting 
insulin and the homeostasis model assessment for β-cell 
function index (Homa-β) [17]. The stimulated total insulin 
secretion was evaluated by AUCINS, while the oral dispo-
sition index (DIo) was used as index of the ability of the 
β-cell to regulate its insulin response to stimuli based on 
differences in insulin sensitivity. DIo was calculated at 
the time 0′ and 30′ during OGTT as described [18], using 
the following formula, where insulin levels are expressed 
in IU/ml and glucose levels in mmol/L: DIo = [Δ insulin 
0′–30′/Δ glucose 0′–30′] × 1/fasting insulin.
As surrogate estimates of insulin sensitivity, we consid-
ered the homeostasis model assessment estimate of insulin 
resistance (Homa-IR) [17], the quantitative insulin sensitiv-
ity check index (QUICKI) [19] and the insulin sensitivity 
index (ISI), a composite index derived from the OGTT and 
validated by Matsuda and DeFronzo [20]. In the control 
subjects, this evaluation was performed only at baseline.
In a subgroup of 11 children, the following day (day 
2) an euglycemic hyperinsulinemic clamp was used to 
determine the insulin sensitivity. One catheter was placed 
in a vein on the forearm for administration of insulin and 
glucose and the second catheter was placed in a vein of 
the contralateral forearm for blood samples. The clamp 
was performed under standard conditions, i.e. the plasma 
insulin concentration was acutely raised with an insulin 
priming (0–3 min: 113.6 mU/m2, 3–6 min: 80.2 mU/m2, 
7–10 min: 50.4 mU/m2 of body surface area) for the first 
10 min of the test and maintained by a continuous infusion 
of insulin infusion (40 mU/m2 for the remaining 110 min). 
The rate of peripheral glucose utilization (M value) was 
calculated by dividing the glucose amount infused dur-
ing the last 40 min by body weight measured in kilograms 
(milligrams per kilogram per minute). The plasma glucose 
concentration was held constant at basal levels by a varia-
ble glucose infusion, and under the steady state conditions 
of euglycemia the glucose infusion rate equalled glucose 
353J Endocrinol Invest (2015) 38:351–359 
1 3
uptake by all the tissues in the body and it was therefore 
considered a measure of tissue sensitivity to exogenous 
insulin [21].
The institutional Ethics Committee of the University of 
Palermo approved this study. At the time of hospitalization, 
an informed consent for the scientific use of the data was 
obtained from both the participants and their parents.
Hormone and biochemical assays
All biochemical data were collected after overnight fast-
ing. Glycemia and HbA1c were measured in the central-
ized accredited laboratories with standard methods. Serum 
insulin was measured by ELISA (DRG Instruments GmbH, 
Germany). The sensitivity of the method was 1 IU/ml. The 
normal insulin range (IU/ml) was 5–19. GH levels were 
assayed by immunoradiometric assay (Radim, Pomezia, 
Italy) and the sensitivity of the assay was 0.05 µg/l. The 
intra- and inter-assay coefficients of variation (CV) were 
2.5–3.9 and 3.8–5.0 %, respectively. Serum total IGF1 was 
assayed in the same laboratory with the ELISA method 
(OCTEIA IGF-I kit, IDS Inc., Fountain Hills, AZ, USA). 
The sensitivity of the method was 1.9 µg/l. The inter- and 
intra-assay CV values were 7–7.1 and 2.3–3.5 %, respec-
tively, at IGF-I levels of 90.7–186 and 66.7-120.9 µg/l, 
respectively. The normal ranges (males and females 
combined) of total IGF-I levels (µg/l) were: 12–108 
(0–1 years); 13–100 (1–3 years); 26–280 (3–6 years); 
85–230 (6–9 years); 98–404 (9–12 years); 142–525 (12–
15 years); 146–415 (15–20 years).
Statistical analysis
The Statistical Packages for Social Sciences SPSS version 
17 was used for data analysis. Baseline characteristics were 
presented as mean ± standard deviation (SD) for continu-
ous variables. Normality of distribution for quantitative 
variables was assessed with the Kolmogorov–Smirnov test. 
Only the M value did not show a normal distribution. The 
differences between paired continuous variables (before 
and after 12 months of therapy) were analyzed by the 
paired t test. Pearson’s correlation was performed among 
continuous variables with normal distribution; correlations 
among continuous variables without normal distribution 
were determined using the Spearman’s test (non-parametric 
equivalent for Pearson test). A p value <0.05 was consid-
ered statistically significant.
Results
The clinical and biochemical features of control subjects, 
GHD children at diagnosis and after 12 months of GH 
treatment are shown in Tables 1 and 2.
Clinical and hormonal profile
No significant difference in height, growth velocity, BMI 
and WC between GHD children at baseline and control 
subjects has been found (Table 1). Conversely, GHD chil-
dren at baseline showed significantly lower IGF-I levels 
Table 1  Clinical and 
biochemical features of GHD 
children at diagnosis (baseline) 
and control subjects
AUC area under the curve, 
OGTT oral glucose tolerance 
test
a
 Mean GH peak after glucagon 
and arginine test
Control group (N = 50) GHD at baseline (N = 73) p
Mean ± SD Mean ± SD
Height (SD) −1.97 ± 0.64 −2.1 ± 0.7 0.646
Growth velocity (cm/year) 4.4 ± 2.1 3.1 ± 1.4 0.112
BMI (kg/m2) 17.52 ± 2.76 17.6 ± 3.2 0.673
BMI (z score) 0.56 ± 0.02 0.52 ± 0.10 0.125
WC (cm) 62.03 ± 9.23 60.9 ± 10.8 0.510
IGF-1 (SD) 0.5 ± 0.2 −1.8 ± 0.5 0.002
GH peaka (µg/l) 15 ± 6.2 3.2 ± 2.5 <0.001
Fasting glucose (mmol/L) 4.5 ± 0.7 4.5 ± 0.5 0.870
Glucose after 120′ OGTT 5.8 ± 0.8 5.4 ± 0.7 0.196
AUCGLU (mmol/L) 12,685 ± 4,090 12,215 ± 1,557 0.625
HbA1c (%) 5.3 ± 0.4 4.8 ± 0.5 0.189
Fasting insulin (IU/ml) 4.9 ± 2.9 5.6 ± 6.4 0.319
AUCINS (IU/ml) 5,758 ± 2,383 4,259 ± 3,868 0.697
Homa-β 117.2 ± 62.8 73.7 ± 22.6 0.268
Oral Disposition Index (DIo) 7.2 ± 8.78 9.2 ± 9.9 0.549
Homa-IR 0.99 ± 0.54 1.1 ± 1.2 0.206
QUICKI 0.4 ± 0.13 0.4 ± 0.06 0.675
ISI-Matsuda 12.7 ± 15.3 15.3 ± 11.9 0.539
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(111.3 ± 56.5 vs. 207.8 ± 190.7 µg/l; p = 0.026) and mean 
GH peak after stimulus (3.2 ± 2.5 vs. 15 ± 6.2 µg/l; 
p < 0.001) than controls.
In the GHD children group the growth significantly 
increased after 12 months of treatment (height −1.6 ± 0.7 
vs. −2.1 ± 0.7 SD; p < 0.001; growth velocity: 8.4 ± 2.5 
vs. 3.1 ± 1.4 cm/year; p < 0.001), with a concomitant sig-
nificant increase in BMI (18.2 ± 2.8 vs. 17.6 ± 3.2 kg/m2; 
p = 0.002), WC (64.9 ± 9.8 vs. 60.9 ± 10.8; p = 0.015) 
and IGF-I levels (309.1 ± 173.9 vs. 111.3 ± 56.5 to µg/l; 
p < 0.001).
Glucose metabolism
No significant difference in glucose metabolism parameters 
between GHD children at baseline and control subjects has 
been found (Table 1).
All GHD children at baseline showed a normal glu-
cose tolerance. The mean fasting and after 120 min dur-
ing OGTT glucose levels were, respectively, 4.5 ± 0.5 and 
5.4 ± 0.7 mmol/L, with a mean HbA1c of 4.8 ± 0.5 %. After 
12 months of GH treatment, a significant increase in fast-
ing glucose (4.9 ± 0.5 vs. 4.5 ± 0.5 mmol/L; p < 0.001) and 
HbA1c levels (5.1 ± 0.4 vs. 4.8 ± 0.5 %; p < 0.001) was doc-
umented, despite all children remained with a normal glucose 
tolerance (Fig. 1). No significant difference was found in 
AUCGLU (12820 ± 3123 vs. 12215 ± 1557 mmol/L; p = 0.491).
IGF-I levels significantly correlated with HbA1c (r 
0.375; p < 0.001) and glucose after OGTT (r 0.300; 
p = 0.040) at baseline and with HbA1c (r 0.121; p = 0.047) 
and fasting glucose (r 0.199; p = 0.010) at 12 months of 
treatment (Table 3).
Insulin secretion indexes
No significant difference in insulin secretion indexes 
between GHD children at baseline and control subjects has 
been found (Table 1).
At baseline, the mean fasting insulin levels were 
5.6 ± 6.4 IU/ml, with a significant increase after 12 months 
of GH treatment (9 ± 6.1 IU/ml; p < 0.001), but with-
out significant increase in AUCINS (4,594 ± 2,439 vs. 
4,259 ± 3,868 IU/ml; p = 0.153).
Homa-β did not show any significant change from 
baseline to 12 months (143.6 ± 144.5 vs. 73.7 ± 22.6; 
p = 0.073), while DIo showed a significant decrease 
(4.6 ± 6.8 vs. 9.2 ± 9.9; p = 0.031). No significant corre-
lation between DIo and the other insulin secretion indexes 
evaluated was found (data not shown).
IGF-I levels significantly and positively correlated 
with fasting insulin both at baseline (r 0.280; p = 0.041) 
and after 12 months (r 0.395; p < 0.001) and negatively 
with DIo both at baseline (r −0.171; p = 0.031) and after 
12 months (r −0.665; p = 0.021) (Fig. 1). No significant 
Table 2  Clinical and 
biochemical features of children 
at diagnosis and after 12 months 
of GH treatment
AUC area under the curve, 
OGTT oral glucose tolerance 
test
a
 Euglycemic hyperinsulinemic 
clamp performed in a subgroup 
of 11 patients
Baseline (N = 73) 12 months (N = 73) p
Mean ± SD Mean ± SD
Height (SD) −2.1 ± 0.7 −1.6 ± 0.7 <0.001
Growth velocity (cm/year) 3.1 ± 1.4 8.4 ± 2.5 <0.001
BMI (kg/m2) 17.6 ± 3.2 18.2 ± 2.8 0.002
BMI (z score) 0.52 ± 0.10 0.59 ± 0.04 <0.001
WC (cm) 60.9 ± 10.8 64.9 ± 9.8 0.015
IGF-I (SD) −1.8 ± 0.5 1.6 ± 1.5 <0.001
Glucose metabolism
 Fasting glucose (mmol/L) 4.5 ± 0.5 4.9 ± 0.5 <0.001
 Glucose after 120′ OGTT 5.4 ± 0.7 5.8 ± 1.1 0.256
 AUCGLU (mmol/L) 12,215 ± 1,557 12,820 ± 3,123 0.491
 HbA1c (%) 4.8 ± 0.5 5.1 ± 0.4 <0.001
Insulin secretion indexes
 Fasting insulin (IU/ml) 5.6 ± 6.4 9 ± 6.1 <0.001
 AUCINS (IU/ml) 4,259 ± 3,868 4,594 ± 2,439 0.536
 Homa-β 73.7 ± 22.6 143.6 ± 144.5 0.073
 Oral Disposition Index (DIo) 9.2 ± 9.9 4.6 ± 6.8 0.031
Insulin sensitivity indexes
 Homa-IR 1.1 ± 1.2 2 ± 1.4 <0.001
 QUICKI 0.4 ± 0.06 0.3 ± 0.04 <0.001
 ISI-Matsuda 15.3 ± 11.9 12.5 ± 7.3 0.069
 M valuea 7.2 ± 2.4 4.4 ± 1.5 0.011
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correlation was found between IGF-I and the other insulin 
secretion indexes (Table 3).
Insulin sensitivity indexes
No significant difference in insulin sensitivity indexes 
between GHD children at baseline and control subjects has 
been found (Table 1).
Homa-IR significantly increased (2.04 ± 1.4 vs. 
1.1 ± 1.2; p < 0.001) from baseline to 12 months of 
GH treatment, with a concomitant decrease in QUICKI 
(0.35 ± 0.04 vs. 0.41 ± 0.06; p < 0.001). ISI Matsuda 
showed a decrease, although not statistically significant 
(12.5 ± 7.3 vs. 15.3 ± 11.9; p = 0.069). A significant 
negative correlation was found between Homa-IR and ISI 
Matsuda at baseline (r −0.420; p = 0.001) but not after 
12 months (r −0.787; p = 0.114) (data not shown).
IGF-I levels significantly and positively correlated 
with Homa-IR both at baseline (r 0.318; p = 0.033) and 
after 12 months (r 0.357; p = 0.004) and negatively with 
QUICKI (r −0.397; p = 0.007) and ISI Matsuda (r −0.429; 
p = 0.007) at baseline (Table 3).
Euglycemic hyperinsulinemic clamp
In the subgroup of 11 children, the M value derived 
from clamp showed a significant decrease from base-
line to 12 months (4.4 ± 1.5 vs. 7.2 ± 2.4; p = 0.011). 
In addition, M value significantly and negatively 
correlated with IGF-I levels at baseline (ρ −0.845; 
p = 0.008) and after 12 months (ρ −0.788; p = 0.012) 
(Table 2). In these patients, a significant positive corre-
lation was found between M value and ISI Matsuda both 
at baseline (ρ 0.950; p = 0.001) and after 12 months (ρ 
0.980; p = 0.001) but not with Homa-IR and QUICKI 
(Table 4).
As additional analysis, we grouped all GHD children 
according to the family history of diabetes and we did not 
find any difference in all metabolic parameters between 
children with or without it. Similarly, when we performed 
the same analysis by grouping all patients according to 
gender, we did not find significant difference between 
males and females (data not shown).
Fig. 1  Time response of glu-
cose (mmol/L) and insulin (IU/
ml) levels during oral glucose 
tolerance test at baseline and 
after 12 months of GH-treat-
ment
Table 3  Correlation (univariate analysis) between IGF-I and glucose 
metabolism, insulin sensitivity and secretion indexes at baseline and 
after 12 months of GH treatment in GHD children
Independent variables Dependent variable: IGF-I
Baseline 12 months
r p r p
Fasting glucose 0.041 0.584 0.199 0.010
Glucose after 120′ OGTT 0.300 0.040 0.122 0.679
AUCGLU 0.270 0.066 0.158 0.664
HbA1c 0.375 <0.001 0.121 0.047
Fasting insulin 0.280 0.041 0.395 <0.001
AUCINS 0.312 0.057 0.103 0.934
Homa-β 0.011 0.944 0.322 0.061
Oral Disposition Index (DIo) −0.171 0.031 −0.665 0.021
Homa-IR 0.318 0.033 0.357 0.004
QUICKI −0.397 0.007 −0.262 0.293
ISI-Matsuda −0.429 0.007 −0.586 0.601
M value −0.845 0.008 −0.788 0.012
Table 4  Correlation (univariate analysis) between the gold standard 
euglycemic hyperinsulinemic clamp (M value) and the other insulin-
sensitivity indexes at baseline and after 12 months of GH treatment in 
GHD children
Independent variables Dependent variable: M value (clamp)
Baseline 12 months
ρ p ρ p
Homa-IR −0.567 0.112 −0.280 0.208
QUICKI 0.566 0.112 0.500 0.667
ISI-Matsuda 0.929 0.003 0.980 0.006
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Discussion
In this prospective study performed in a large cohort of pre-
pubertal children affected by idiopathic GHD we showed 
that after 12 months of GH treatment a decrease in insulin 
sensitivity and impairment in insulin secretion relative to 
insulin sensitivity occur, even without evident changes in 
glucose tolerance.
Decreased insulin sensitivity and impaired pancreatic 
β-cell function are the two key components in the patho-
genesis of type 2 diabetes mellitus. Therefore, assessment 
of insulin sensitivity and secretion in children potentially 
at risk of glucose metabolism impairment, as during GH 
treatment, is of crucial importance. As several studies have 
reported, GH plays an important role in glucose and insulin 
metabolism, but the data about the metabolic effects of GH 
treatment in GHD patients are controversial.
A degree of insulin resistance in untreated GHD adults 
with an increased insulin sensitivity after GH therapy has 
been documented [22, 23] while other studies did not find 
any metabolic difference between untreated GHD adults 
and control subjects, or any variation after GH therapy [24]. 
In GHD children, the effect of GH therapy on insulin lev-
els has also been reported. Indeed, a trend towards reduced 
insulin sensitivity with a compensatory hyperinsulinemic 
response or increased insulin levels, but with normal glu-
cose levels, after GH treatment has been demonstrated [12, 
25]. We already demonstrated an increase in HOMA-IR, 
related to increased insulin levels and without any unto-
ward effects on glucose metabolism, in a small group of 
GHD children after GH treatment [26]. Our current results 
are in line with these data. We found an increase in insulin 
and Homa-IR values, correlated with IGF-I levels, with a 
concomitant decrease in QUICKI, after 12 months of GH 
treatment. The concomitant increase in fasting glucose and 
HbA1c levels, correlated with IGF-I, does not reach clini-
cally significant values, as they remained within the limits 
of normality. In addition, only fasting glucose showed a sig-
nificant increase, while no significant change was found in 
glucose after OGTT and in AUCGLU, and these data could 
explain the maintenance of normal glucose tolerance after 
12 months of GH treatment. These data are not consistent 
with those of Cutfield et al. [14], which reported from a ret-
rospective analysis of data from an international pharmaco-
epidemiological survey an increased incidence of diabetes 
mellitus or impaired glucose tolerance in population of 
children and adolescents at higher risk for glucose intoler-
ance receiving GH treatment, as if GH treatment may be an 
acceleration of the disorder in predisposed individuals and 
the metabolic impairment condition may be reversible by 
stopping or reducing the dose. This difference is probably 
also due to the short follow-up in our cohort of patients. 
Indeed, given the limited period of observation, our data 
do not exclude the possibility that a clear glucose intoler-
ance may develop with longer duration of GH treatment. 
Notably, the estimates of insulin sensitivity, as well as of 
pancreatic β-cell function, derived from fasting insulin 
and glucose have not always been demonstrated to be use-
ful surrogate measures of insulin sensitivity and secretion. 
The gold standard for measuring insulin sensitivity and 
secretion is hyperinsulinemic-euglycemic and hypergly-
cemic clamps, respectively [21, 27], but very few studies 
used these methods in GHD children. Indeed, these inva-
sive and expensive procedures are not applicable to routine 
clinical practice and in a large number of patients. In our 
study, we also used the euglycemic clamp in a subgroup 
of children to evaluate the insulin-stimulated glucose uti-
lization ant to compare it with the other insulin sensitivity 
indexes assessed. Our data derived from the clamp support 
the evidence of a decrease in insulin sensitivity after GH 
treatment. In healthy subjects, the insulin sensitivity state 
assessed by euglycemic clamp seems to strongly correlate 
with Homa-IR and QUICKI [28, 29]. Conversely, Schwartz 
et al. [30] found that surrogate measures of insulin sensi-
tivity are only modestly correlated with the clamp meas-
ures and they concluded that these indexes do not offer 
any advantage over fasting insulin. In our study, among 
the insulin sensitivity indexes, we found a strong correla-
tion between M value and ISI Matsuda both at baseline 
and after 12 months of GH treatment, while no correlation 
was found between the gold standard clamp and the other 
indexes evaluated. These data lead to the conclusion that, 
in our cohort of GHD children and during a follow-up of 
12 months, the surrogate indexes Homa-IR and QUICKI 
probably do not represent useful and reliable indexes of the 
real degree of insulin sensitivity.
Also with regard to the evaluation of insulin secre-
tion, the existing data in the literature about the effect of 
GH treatment are controversial. Heptulla et al. [12] dem-
onstrated with the hyperglycemic clamp procedure an 
increase in insulin secretion after GH therapy, without 
change in fasting glucose. The authors concluded that 
glucose-stimulated insulin responses are increased in chil-
dren treated with GH and that hyperinsulinemic responses 
compensate for reductions in insulin sensitivity and could 
be useful to amplify insulin effects on protein metabolism. 
Conversely, in adult GHD subjects GH treatment has been 
demonstrated to have a negative effect on the β-cell func-
tion, in terms of an inadequate adaptation in insulin secre-
tion as the insulin sensitivity deteriorates [31]. A correlation 
between the insulin secretion assessed by hyperglycemic 
clamp and fasting insulin or Homa-β has been documented 
by some studies [29, 30]. Our data are partially in line with 
these results. Indeed, if the significant increase in fasting 
insulin concentrations could indicate that insulin secretion 
was increased by GH treatment, in our patients Homa-β did 
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not show a significant change after GH treatment, despite 
its trend to increase, as well as the total insulin secretion 
(AUCINS). Conversely, when we analyzed the insulin secre-
tion with DIo, which has been tested few times in GHD 
children, a worsening of insulin secretion relative to insu-
lin resistance, correlated with IGF-I levels, was observed. 
DIo, which expresses the ability of β-cells to adequately 
compensate for insulin resistance through increased insulin 
secretion, has been shown to be a predictor of glucose lev-
els after OGTT in obese adolescents [32, 33] and of devel-
opment of diabetes in adults [18] and it has been shown to 
decline well before glucose levels significantly rise into the 
diabetic range [34, 35]. Our results are in line with these 
data. Indeed, we observed that after 12 months of GH treat-
ment the impairment in insulin secretion relative to insulin 
sensitivity is apparent even with normal glucose tolerance. 
These data are also in agreement with those of Burns et al. 
[36], which showed a decline in β-cell function relative to 
insulin sensitivity with increasing fasting glucose levels in 
the non-diabetic range in children, and those of Jensen et 
al. [37], which demonstrated reduced DIo in a large cohort 
of children born small for gestational age after the first year 
of GH treatment.
In our hypothesis, if a direct trophic effect of GH on 
the pancreatic β-cells can not be ruled out to explain the 
increase in fasting insulin secretion [38, 39], the decrease 
in DIo can be considered an early marker of inadequate 
β-cell compensation to decreased insulin sensitivity. More 
exhaustive information about the effect of GH on β-cell 
function can come from future studies that will also ana-
lyze the secretion of basal and stimulated C-peptide.
A limit of this study is represented by the lack of data 
of the control group after 12 months of follow-up. Indeed, 
we can not exclude with certainty that the results are due 
to some other factor, in addition to the treatment with GH. 
For example, the impact of the deletion of exon 3 in the GH 
receptor gene (GHRd3) on insulin secretion and sensitivity 
has been documented both in healthy subjects and in GHD 
children, adolescents and adults [40–42] and the presence of 
the GHRd3 allele was associated with higher DIo [40, 41].
In addition, even if the pubertal stage did not change 
in all children during the entire follow-up, a role of some 
slightest change in DHEAS, estrogen or testosterone lev-
els can not be ruled out, although nobody changed puber-
tal stage at visual inspection and no difference was found 
between males and females. Additional case–control stud-
ies with a larger number of patients will better clarify this 
aspect.
Lastly, in line with the discordant data that exist about 
the different metabolic effects of GH treatment accord-
ing to the different dose used [43, 44], a larger prospective 
study where patients are randomized to different GH doses 
can give more complete information.
In conclusion, 12 months of GH treatment in GHD chil-
dren, regardless of family history of diabetes, lead to a trend 
of worsening of glucose metabolism, which still remains in 
the normal range, associated with a significant reduction 
in insulin sensitivity and with an inadequate β-cell capac-
ity to counteract the increase in insulin resistance. The sur-
rogate Homa-IR and QUICKI probably do not represent 
useful and reliable indexes of the real degree of insulin 
sensitivity. Conversely, DIo has proven to be the most use-
ful indicator of deterioration of glucose metabolism. How-
ever, data about the cut-offs expressing the normal range 
of DIo in children and adolescents with different age and 
pubertal stage and strong suggestions about the behavior of 
this index during the pediatric age are missing. Therefore, 
the use of DIo, which in the current study seemed useful 
to show a degree of glucose metabolism impairment even 
in cases in which the overt glucose abnormalities have not 
yet appeared during the follow-up of GH-treated children, 
must be validated in additional prospective larger studies 
with longer follow-up.
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